Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Refine sua pesquisa

Collapse All  Ocultar
Expand All  Mostrar

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 309
1.

Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.

Autor(es): Lin, Cai; Sun, Chenghai; Liu, Xiao; Zhou, Yiqian; Hussain, Muzammal; Wan, Junting; Li, Minke; Li, Xue; Jin, Ruiliang; Tu, Zhengchao; Zhang, Jiancun
Fonte: Antiviral Res;129: 13-20, 2016 May.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26802557
Resumo: Among many subtypes of influenza A viruses, influenza A(H1N1) and A(H3N2) subtypes are currently circulating among humans (WHO report 2014-15). Therapeutically, the emergence of viral resistance to currently available drugs (adamantanes and neuraminidase inhibitors) has heightened alarms for developing novel drugs that could address diverse targets in the viral replication cycle in order to improve treatment outcomes. To this regard, the design and synthesis of nucleoside analog inhibitors (mais)
2.

Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.

Autor(es): Batool, Sidra; Mushtaq, Gohar; Kamal, Warda; Kamal, Mohammad A
Fonte: Med Chem;12(1): 63-73, 2016.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26152143
Resumo: Oseltamivir and Zanamivir are two of the recently licensed neuraminidase inhibitors used for the treatment of influenza. However, alternative antiviral agents are needed due to the development of resistant mutations in Oseltamivir subtype H1N1 and H5N1 avian influenza A viruses, the latter being a highly pathogenic avian virus that can be transferred to humans upon immediate contact with H5N1 infected poultry or surface. Novel drug inhibiting group 1 neuraminidases may potentially be develo (mais)
3.

Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.

Autor(es): Ann, Julie; Abed, Yacine; Beaulieu, Edith; Bouhy, Xavier; Joly, Marie-Hélène; Dubé, Karen; Carbonneau, Julie; Hamelin, Marie-Eve; Mallett, Corey; Boivin, Guy
Fonte: Influenza Other Respir Viruses;10(2): 122-6, 2016 Mar.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26526406
Resumo: Viral fitness of a laninamivir-selected influenza A/Brisbane/10/2007-like (H3N2) isolate (LRVp9) containing a 237-amino acid neuraminidase deletion and a P194L hemagglutinin mutation was evaluated in vitro and in ferrets. LRVp9 and the wild-type (WT) virus showed comparable replication kinetics in MDCK-ST6GalI cells. Cultured virus was recovered between days 2 and 5 post-infection in nasal washes (NW) from the 4 WT-infected ferrets whereas no virus was recovered from the LRVp9-infected ani (mais)
4.

NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.

Autor(es): Lytras, Theodore; Kossyvakis, Athanasios; Mentis, Andreas
Fonte: Antiviral Res;126: 18-20, 2016 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26692213
Resumo: The results of neuraminidase inhibitor (NAI) enzyme inhibition assays are commonly expressed as 50% inhibitory concentration (IC50) fold-change values and presented graphically in box plots (box-and-whisker plots). An alternative and more informative type of graph is the kernel density plot, which we propose should be the preferred one for this purpose. In this paper we discuss the limitations of box plots and the advantages of the kernel density plot, and we present NAIplot, an opensource (mais)
5.

Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.

Autor(es): Sugaya, Norio; Sakai-Tagawa, Yuko; Bamba, Masahiro; Yasuhara, Rieko; Yamazaki, Masahiko; Kawakami, Chiharu; Yamaguchi, Yoshio; Ide, Yoshiaki; Ichikawa, Masataka; Mitamura, Keiko; Kawaoka, Yoshihiro
Fonte: Antivir Ther;20(1): 49-55, 2015.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 24832015
Resumo: BACKGROUND: Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness. METHODS: We compared the virus isolation rates of children with pandemic A H1N1/09 influenza infection and children with A H3N2 influenza (mais)
6.

Primarily oseltamivir-resistant influenza A (H1N1pdm09) virus evolving into a multidrug-resistant virus carrying H275Y and I223R neuraminidase substitutions.

Autor(es): Grund, Sebastian; Gkioule, Charikleia; Termos, Tahani; Pfeifer, Nico; Kobbe, Guido; Verheyen, Jens; Adams, Ortwin
Fonte: Antivir Ther;20(1): 97-100, 2015.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 24941247
Resumo: Antiviral susceptibility testing and reporting of viruses carrying amino acid substitutions conferring antiviral drug resistance is essential to assess the spread and clinical impact of these viruses. Here, we report on a patient who was infected with a primarily oseltamivir-resistant influenza A (H1N1pdm09) virus following allogeneic stem cell transplantation and rituximab treatment. Under prolonged virus replication and zanamivir therapy the neuraminidase amino acid substitutions H275Y an (mais)
7.

Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.

Autor(es): Correia, Vanessa; Santos, Luis A; Gíria, Marta; Almeida-Santos, Maria M; Rebelo-de-Andrade, Helena
Fonte: J Med Virol;87(1): 45-56, 2015 Jan.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 25042157
Resumo: Neuraminidase inhibitors (NAIs) oseltamivir and zanamivir are currently the only effective antiviral drugs available worldwide for the management of influenza. The potential development of resistance is continually threatening their use, rationalizing and highlighting the need for a close and sustained evaluation of virus susceptibility. This study aimed to analyze and characterize the phenotypic and genotypic NAIs susceptibility profiles of A(H1N1)pdm09 viruses circulating in Portugal from (mais)
9.

Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons.

Autor(es): Zaraket, Hassan; Dapat, Clyde; Ghanem, Soha; Ali, Zainab; Lteif, Mireille; Kondo, Hiroki; Dapat, Isolde C; Saito, Kousuke; Kayali, Ghazi; Suzuki, Hiroshi; Dbaibo, Ghassan; Saito, Reiko
Fonte: Intervirology;57(6): 344-52, 2014.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 25301400
Resumo: OBJECTIVE: To genetically characterize human influenza viruses and their susceptibilities to antivirals during two post-pandemic seasons in Lebanon. METHODS: Influenza virus was isolated from nasopharyngeal swabs that were obtained from patients with influenza-like illness during 2010-2012 and further analyzed both phenotypically and genotypically. RESULTS: During the 2010-2011 season, both 2009 pandemic H1N1 (H1N1p) and B viruses co-circulated with equal prevalence, while the H3N2 virus pr (mais)
10.

Influenza viruses resistant to neuraminidase inhibitors.

Autor(es): Nitsch-Osuch, Aneta; Brydak, Lidia Bernadeta
Fonte: Acta Biochim Pol;61(3): 505-8, 2014.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 25195142
Resumo: Neuraminidase inhibitors (NAIs) are antiviral drugs for treatment and prophylaxis of influenza. By blocking the activity of the enzyme neuraminidase, NAIs prevent new viral particles from being released. The increasing use of NAIs brings into focus the risk of drug resistance arising to the class. There are three levels of antiviral resistance according to the way that resistance can be detected or inferred: genotypic, phenotypic and clinical resistance. For many years seasonal influenza vi (mais)
11.

Glycan based detection and drug susceptibility of influenza virus.

Autor(es): Dinh, Hieu; Zhang, Xiaohu; Sweeney, Joyce; Yang, Yang; He, Yun; Dhawane, Abasaheb; Iyer, Suri S
Fonte: Anal Chem;86(16): 8238-44, 2014 Aug 19.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 25007351
Resumo: We have developed a panel of synthetic glycans as receptor mimics for the specific capture of influenza viruses. The glycans were printed onto commercial glass slides using a free amine at the end of a spacer to generate a small focused microarray. The microarray was evaluated for its ability to capture three different strains of influenza A virus, two H1N1, A/Brisbane/59/2007 and A/Solomon Islands/3/2006 and one H3N2, A/Aichi/2/1968. We observed an excellent detection ability with some com (mais)
12.

Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.

Autor(es): Perez-Sautu, U; Pozo, F; Cuesta, I; Monzon, S; Calderon, A; Gonzalez, M; Molinero, M; Lopez-Miragaya, I; Rey, S; Cañizares, A; Rodriguez, G; Gonzalez-Velasco, C; Lackenby, A; Casas, I
Fonte: Euro Surveill;19(27): 14-20, 2014 Jul 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 25033052
Resumo: The Y155H amino acid substitution in the neuraminidase gene (NA) has previously been associated with highly reduced inhibition by neuraminidase inhibitors in the seasonal H1N1 influenza A virus which circulated in humans before the 2009 pandemic. During the 2012/13 epidemic season in Spain, two A(H1N1) pdm09 viruses bearing the specific Y155H substitution in the NA were detected and isolated from two patients diagnosed with severe respiratory syndrome and pneumonia requiring admission to th (mais)
Resultados  1-12 de 309